MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
32.70
+1.31
+4.17%
Pre Market: 33.30 +0.6 +1.83% 04:58 05/09 EDT
OPEN
31.19
PREV CLOSE
31.39
HIGH
33.26
LOW
30.67
VOLUME
112
TURNOVER
--
52 WEEK HIGH
62.53
52 WEEK LOW
24.10
MARKET CAP
3.06B
P/E (TTM)
-8.8524
1D
5D
1M
3M
1Y
5Y
1D
Crinetics Pharmaceuticals: Promising Outlook with Paltusotine Approval and Strategic Market Positioning
TipRanks · 7h ago
*Crinetics Pharmaceuticals Cash, Cash Equivalents, Investment Securities Anticipated to Provide Runway Into 2029 >CRNX
Dow Jones · 12h ago
*Crinetics Pharmaceuticals 1Q Rev $361,000 >CRNX
Dow Jones · 12h ago
*Crinetics Pharmaceuticals $1.3B in Cash, Cash Equivalents, and Investment Securities as of March 31 >CRNX
Dow Jones · 12h ago
Crinetics Pharmaceuticals GAAP EPS of -$1.04 misses by $0.11, revenue of $0.36M beats by $0.26M
Seeking Alpha · 12h ago
Crinetics Pharmaceuticals Q1 EPS $(1.04) Misses $(0.93) Estimate, Sales $361.00K Beat $90.91K Estimate
Benzinga · 12h ago
Press Release: Crinetics Pharmaceuticals Reports -2-
Dow Jones · 13h ago
*Crinetics Pharmaceuticals 1Q Loss/Shr $1.04 >CRNX
Dow Jones · 13h ago
More
About CRNX
More
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Recently
Symbol
Price
%Change

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.